Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives

Vyssoulis, Gregory P.; Karpanou, Eva A.; Pitsavos, Christos; Paleologos, Athanasios A.; Kourtis, Tsabikos K.; Toutouzas, Pavlos

doi:10.1007/bf00053433

Cited by 6 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ketanserin was recently reported to achieve regression of LV hypertrophy in older hypertensive patients without concomitant deleterious effects on LV function [27,28]. These findings in nine and 13 patients followed for 12 months corroborate earlier data and are similar to those of the present study [10,29].…”

Section: Discussionsupporting

confidence: 83%

“…A pilot study on left ventricular hypertrophy regression with ketanserin antihypertensive treatment in older subjects (>60 years old) was carried out in our center [10], while in an earlier study celiprolol was documented to have similar efficacy in younger patients [15]. To compare the relative power of these two drugs, 60 new patients over 55 years old were recruited and followed for 2 years, after written informed consent was obtained, in a randomized openlabel, long-term ongoing study of essential hypertension.…”

Section: Methodsmentioning

confidence: 99%

“…It has been shown to cause regression of LV hypertrophy in elderly persons [9,10]. Betaadrenergic blockers can also cause some degree of LV hypertrophy regrssion; however, they are not widely used in older patients because of their negative inotropic action, drug-induced conduction defects, and excessive bradycardia [11][12][13].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients

Vyssoulis

Karpanou

Pitsavos

et al. 1992

Cardiovasc Drug Ther

Self Cite

View full text Add to dashboard Cite

The effects of ketanserin, a specific serotonin2-receptor agonist, and celiprolol, a new, highly cardioselective beta 1 blocker with partial beta 2 agonist activity and peripheral vasodilating properties, on left ventricular (LV) structure and function were assessed in 60 older hypertensive patients (greater than 55 years) with clinical LV hypertrophy (LV mass index greater than 130 g/m2). The patients were studied using echocardiography after 1 month of placebo treatment, and 6 and 18 months of monotherapy with active drug. Ketanserin and celiprolol lowered blood pressure to normal levels. Heart rate did not change with ketanserin and fell moderately (-5%) with celiprolol (p less than .001). Regression of LV hypertrophy was achieved with the use of either medication (p less than .0001), although the magnitude of reduction in LV mass was greater with celiprolol at both 6 months (-10% vs -5%, p = .001) and 18 months (-13% vs -7%, p = .002). While LV volume did not change with either drug, celiprolol tended to decrease it, resulting in a 5% reduction in cardiac index (p = .01), which was associated with mild bradycardia. Ketanserin did not change LV ejection fraction, whereas celiprolol caused a slight (1.5%) long-term improvement (p = .003). Systolic wall stress and total peripheral resistance decreased with both agents (p less than .01), with no between-group differences. In conclusion, anti-hypertensive treatment of older persons with ketanserin or celiprolol achieves regression of LV hypertrophy without associated deleterious effects on LV function.

show abstract

Section: Discussionsupporting

confidence: 83%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients

Vyssoulis

Karpanou

Pitsavos

et al. 1992

Cardiovasc Drug Ther

Self Cite

View full text Add to dashboard Cite

show abstract

“…Several trials have demonstrated the possibility of reducing LV mass in young adult[34, 83,84] and elderly patientsPI,52, [85][86][87][88][89] To achieve this, it is necessary to treat the underlying conditions of LVH, particularly hypertension, ischaemic and valvular heart disease and obesity. Roman and colleagues [90] showed that aortic valve replacement normalised LV mass in two-thirds of patients with aortic stenosis.…”

Section: Managementmentioning

confidence: 99%

“…Less prescribed hypotensive drugs like methyldopa,[1l2] prazosin,[ll3] and ketanserin, [89] can also induce LV mass reduction. However, this was not observed after 6 months of therapy with minoxidil or hydralazine.…”

Section: Managementmentioning

confidence: 99%

Left Ventricular Hypertrophy

Paciaroni¹,

Fraticelli²

1995

Drugs & Aging

View full text Add to dashboard Cite

Left ventricular hypertrophy (LVH) can be detected by electrocardiography or, with greater sensitivity, by echocardiography. Its prevalence increases with age, probably due to greater disease diffusion rather than aging itself. LVH is not only a consequence of disease, but also an independent contributor to morbidity and mortality, both in young and aged populations. Attempts have been made to reduce left ventricular (LV) mass by pharmacological and other means. LVH regression is possible in young and old hypertensive patients by some but not all hypotensive drugs. The effect on LV mass seems largely independent of blood pressure reduction. Whether LV mass control should be sought beyond the treatment of the underlying disease is still debated. Preliminary data indicate prognostic benefits associated with LVH regression, but studies on the elderly are scanty. LVH is a common and ominous finding in old people. In hypertension it can be reversed by drug therapy, with apparent functional improvement. Further studies are needed to verify the long term consequence of LV mass reduction in this age group.

show abstract

Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice

Lairez,

Cognet,

Schaak

et al. 2013

J Neural Transm

View full text Add to dashboard Cite

Serotonin, in addition to its fundamental role as a neurotransmitter, plays a critical role in the cardiovascular system, where it is thought to be involved in the development of cardiac hypertrophy and failure. Indeed, we recently found that mice with deletion of monoamine oxidase A had enhanced levels of blood and cardiac 5-HT, which contributed to exacerbation of hypertrophy in a model of experimental pressure overload. 5-HT2A receptors are expressed in the heart and mediate a hypertrophic response to 5-HT in cardiac cells. However, their role in cardiac remodeling in vivo and the signaling pathways associated are not well understood. In the present study, we evaluated the effect of a selective 5-HT2A receptor antagonist, M100907, on the development of cardiac hypertrophy induced by transverse aortic constriction (TAC). Cardiac 5-HT2A receptor expression was transiently increased after TAC, and was recapitulated in cardiomyocytes, as observed with 5-HT2A in situ labeling by immunohistochemistry. Selective blockade of 5-HT2A receptors prevented the development of cardiac hypertrophy, as measured by echocardiography, cardiomyocyte area and heart weight-to-body weight ratio. Interestingly, activation of calmodulin kinase (CamKII), which is a core mechanism in cardiac hypertrophy, was reduced in cardiac samples from M100907-treated TAC mice compared to vehicle-treated mice. In addition, phosphorylation of histone deacetylase 4 (HDAC4), a downstream partner of CamKII was significantly diminished in M100907-treated TAC mice. Thus, our results show that selective blockade of 5-HT2A receptors has beneficial effect in the development of cardiac hypertrophy through inhibition of the CamKII/HDAC4 pathway.

show abstract

Left ventricular hypertrophy regression and function changes with ketanserin in elderly hypertensives

Cited by 6 publications

References 10 publications

Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients

Comparison of ketanserin and celiprolol on regression of left ventricular hypertrophy in older hypertensive patients

Left Ventricular Hypertrophy

Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice

Contact Info

Product

Resources

About